Jordan Johnson, Founder and Principal at Bridge Oncology and Legal Data Expert, shared a post on LinkedIn:
“CMS Releases the CY 2027 OPPS Proposed Rule (CMS-1850-P).
The CY 2027 Outpatient Prospective Payment System (OPPS) Proposed Rule is more than a routine payment update. It will have a significant impact on strategic planning, budgeting, reimbursement, compliance, pharmacy operations, and oncology service line performance for 2027 and beyond.
The team at Bridge Oncology has begun a comprehensive analysis of the more than 1,800-page proposed rule, including the APC files and reimbursement changes that matter most to healthcare leaders.
Early observations include:
- Significant proposed APC increases across much of Radiation Oncology.
- Important changes affecting 340B reimbursement strategy.
- Continued evolution of drug reimbursement and oncology pharmacy payment methodology.
- Site-neutral payment proposals that could impact hospital-owned infusion centers.
- Updates affecting theranostics, radiopharmaceuticals, proton therapy, infusion services, Comprehensive APCs (C-APCs), and outpatient oncology operations.
- Operational and financial implications for CFOs, Pharmacy Directors, Cancer Center Administrators, Revenue Cycle leaders, Compliance Officers, and Radiation Oncology executives.
Over the coming days, Bridge Oncology will provide executive-level summaries covering:
- Radiation Oncology financial impact.
- Proton Therapy.
- 340B Strategy.
- Infusion and Pharmacy.
- Comprehensive APC Changes.
- Revenue Cycle and Charge Capture.
- Compliance and Operational Readiness.
- Executive Financial Modeling.
Organizations that understand these changes early will have a significant advantage as they prepare for 2027.
The proposed rule is only the beginning – planning starts now. Bridge Oncology will continue to provide practical analysis that translates CMS policy into actionable operational and financial strategies.”
Other articles about Radiation Oncology on OncoDaily.